Navigation Links
Study drug is first to help patients with recurrent low-grade ovarian cancer
Date:2/8/2013

HOUSTON - Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails.

"After surgery, with or without pre-surgical chemotherapy, when low-grade serous ovarian cancer persists or returns, chemotherapy and hormonal therapy are relatively ineffective," said David Gershenson, M.D., professor in The University of Texas MD Anderson Cancer Center Department of Gynecological Oncology and Reproductive Medicine.

Response rates for treatment are measured in single digits. Gershenson and colleagues have spent the greater part of 20 years characterizing the disease, which makes up 10 percent of ovarian cancer cases, and searching for new ways to treat it. Cancer recurs or persists in 80 to 85 percent of patients.

A phase II clinical trial by the National Cancer Institute's Gynecological Oncology Group provides the first evidence of a drug that shows a relatively high response rate for these patients.

Selumetinib halts growth or shrinks tumors

In the first-targeted therapy clinical trial for low-grade serous ovarian cancer, eight of 52 (15 percent) patients had a complete or objective partial response (tumor shrinkage) and 34 (65 percent) had no disease progression during the two-year course of the study. Study results appear in the February edition of The Lancet Oncology.

"These are remarkably encouraging results for what can ultimately be a devastating disease," said Gershenson, the paper's senior author.

These patients have a median overall survival of 80 months, about twice as long as those with high-grade disease, who are typically in their 60s when diagnosed and comprise 90 percent of ovarian cancer patients. The average age of women with low-grade cancer falls in the early 40s, Gershenson said, and it's not uncommon to see women in their 20s, 30s and 40s and the occasional teenager with the d
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study drug is first to help patients with recurrent low-grade ovarian cancer
(Date:2/28/2015)... (PRWEB) March 01, 2015 Heart diseases ... that 10 percent of urban adult population and 5 ... of heart diseases and 20-30 percent of them require ... heart ailments and coronary vascular diseases (CVD). , A ... a new market research report titled “Indian Coronary Stent ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The ... is offering a new special. Throughout all of ... , This service can help ... problems and pain. Patients may notice certain symptoms that ... relining. These symptoms include: , 1.    Pain, clicking, and ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 A study ... promising new gene therapy procedure for the treatment of ... in patients. Authored by Dr. Robert MacLaren, ... published in the Lancet Medical Journal on January 16, ... choroideremia, a rare genetic disorder that mostly affects men ...
(Date:2/28/2015)... February 28, 2015 Dr. Perry ... Coast area residents, recently announced a special offer for ... a treatment option for new and established patients at ... with a bright, white smile, Dr. Patel and his ... $299, marked down from the regular price of $450. ...
(Date:2/28/2015)... York, NY (PRWEB) February 28, 2015 On ... Phishing Kits Make It Easy For Scammers To Steal Your ... anyone can get their hands on a DIY phishing kit, ... But it also touched on another important point about how ... these kits are often implemented, “like compromising legitimate content management ...
Breaking Medicine News(10 mins):Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4
... FRIDAY, March 18 (HealthDay News) -- Obstructive sleep apnea may ... with enlarged prostates, a new study suggests. The study ... benign prostate enlargement (BPE) and reported nighttime urination (nocturia) at ... of same-age men who had no BPE and one or ...
... 18 (HealthDay News) -- Women in smoke-free homes and ... breast cancer, new research shows. U.S. researchers compared ... of breast cancer incidence and death. States with higher ... breast cancer deaths, particularly among younger premenopausal women. ...
... College of Radiology,s Imaging Network (ACRIN) and the ... (NCI) Clinical Trials Cooperative Group members, today announced ... programs. The groups plan to form ... new organization will include three areas of research ...
... with different terms to describe a clinical trial, parents were far ... called a "research study" than if it was called a "medical ... the former as safer, even though that was not necessarily the ... Human Research . Terms such as these are ...
... News) -- Anti-drug ads appear to be an effective way ... the United States, a new study has found. In ... Influence" anti-drug campaign, researchers analyzed the relationship between exposure to ... students in grades 8, 10 and 12. The campaign ...
... The federal Centers for Disease Control and Prevention ... Health & Hospitals System and Rush University Medical ... successful program aimed at preventing healthcare-associated infections, antibiotic ... The project, dubbed the Chicago Antimicrobial Resistance and ...
Cached Medicine News:Health News:Sleep Disorder May Spur Men to Head to Bathroom at Night 2Health News:Biomarker-driven science at the heart of new ACRIN-ECOG structure 2Health News:Biomarker-driven science at the heart of new ACRIN-ECOG structure 3Health News:Terminolgy matters in parents' willingness to enroll their children in research 2Health News:CDC, Cook County and Rush collaborate to research and prevent hospital infections 2Health News:CDC, Cook County and Rush collaborate to research and prevent hospital infections 3Health News:CDC, Cook County and Rush collaborate to research and prevent hospital infections 4
(Date:2/27/2015)... HILL, N.C. , Feb. 27, 2015 ... over the past decade but one thing hasn,t changed: ... MSLs to build relationships with Key Opinion Leaders. ... recognized as the most valuable type of interaction, field ... limits on their KOL interactions. This is just one ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... from a pre-clinical study published in the ... ( www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib (IMBRUVICA ... (a checkpoint inhibitor), suppression of tumor growth was ... when treating certain hematologic cancers and solid tumors ...
(Date:2/27/2015)... TEL-AVIV , Israele, February 27, 2015 /PRNewswire/ ... continua nel suo sviluppo dell,innovativo sistema di monitoraggio ... il primo trial sull,uomo-   ... operante nello sviluppo di nuovo sistema per il ... congestizio (CHF), ha annunciato oggi di aver concluso ...
Breaking Medicine Technology:Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
... ResMed Inc. (NYSE: RMD ) today announced results ... quarter ended September 30, 2011 was a record $314.8 million, ... basis) over the quarter ended September 30, 2010.  For the ... Largely as a result of currency exchange rate movements, net ...
... of the most crucial components of a successful new ... relationships with the FDA. However, while building a collegial and ... the FDA is not always an easy task, not doing ... study participant, a Regulatory Affairs Executive Director at a leading ...
Cached Medicine Technology:ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011 2ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011 3ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011 4ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011 5ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011 6Recent Research Provides Formula for Timely Product Launch: Good Science + Effective FDA Relations 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: